XOMA
XOMA Royalty Corp. NASDAQ Listed Jun 6, 1986$42.02
+0.30%
vs $41.89
Mkt Cap $526.9M
52w Low $22.29
96.1% of range
52w High $42.81
50d MA $41.00
200d MA $33.24
P/E (TTM)
23.9x
EV/EBITDA
15.7x
P/B
7.3x
Debt/Equity
1.3x
ROE
37.8%
P/FCF
263.2x
RSI (14)
54.40
ATR (14)
$0.36
Beta
0.68
50d MA
$41.00
200d MA
$33.24
Avg Volume
108.3K
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
2200 Powell Street · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | — | — | — | 41.75 | +0.3% | +0.1% | +0.5% | -0.6% | -0.3% | -0.2% | — |
| May 12, 2026 | BMO | 0.19 | 0.18 | -5.3% | 41.50 | +0.1% | +0.6% | +0.1% | +0.5% | -0.6% | -0.3% | — |
| Mar 18, 2026 | BMO | -0.13 | 0.12 | +192.3% | 27.35 | +1.3% | +5.2% | -0.2% | +3.7% | -1.8% | +3.4% | — |
| Nov 12, 2025 | BMO | -0.02 | -0.35 | -1650.0% | 33.62 | +2.0% | -4.1% | +1.2% | -1.9% | +2.4% | +1.1% | — |
| Aug 13, 2025 | BMO | -0.12 | 0.48 | +500.0% | 30.89 | +1.0% | +2.3% | -0.7% | +1.2% | +1.0% | +1.2% | — |
| May 13, 2025 | BMO | -0.26 | 0.06 | +123.1% | 27.49 | -1.2% | -2.7% | +0.6% | +0.3% | +1.8% | -3.2% | — |
| Mar 17, 2025 | BMO | -0.29 | -0.46 | -58.6% | 20.73 | +1.3% | +0.8% | +0.0% | +0.8% | -0.9% | +0.2% | — |
| Nov 7, 2024 | BMO | -0.44 | -0.39 | +11.4% | 30.20 | +1.6% | +2.5% | +0.6% | +0.3% | -5.0% | +0.6% | — |
| Aug 13, 2024 | BMO | -0.26 | -0.28 | -7.7% | 26.46 | +0.9% | -1.1% | +6.3% | +1.1% | +4.5% | -2.4% | — |
| May 9, 2024 | BMO | -0.71 | -0.86 | -21.1% | 23.69 | +2.5% | +7.4% | +1.3% | -0.7% | -3.4% | +3.8% | — |
| Mar 8, 2024 | BMO | -0.36 | -0.49 | -36.1% | 24.71 | -0.9% | +6.4% | -2.4% | -0.2% | +0.6% | +2.1% | — |
| Nov 7, 2023 | BMO | -0.48 | -0.60 | -25.0% | 16.26 | -0.3% | -6.2% | -0.7% | +5.6% | -0.6% | +1.1% | — |
| Aug 8, 2023 | BMO | -0.52 | -0.59 | -13.5% | 15.65 | +4.5% | +3.2% | +0.9% | +0.6% | -3.5% | -2.1% | — |
| May 9, 2023 | AMC | -0.50 | -0.98 | -96.0% | 18.31 | +0.7% | +2.7% | -1.3% | +3.2% | +4.8% | +2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.76 | $28.89 | +0.5% | -0.2% | +3.7% | -1.8% | +3.4% | +1.1% |
| Feb 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $25.32 | $25.79 | +1.9% | +6.8% | -1.1% | +0.1% | -4.6% | +2.7% |
| Dec 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $34.36 | $27.90 | -18.8% | -22.8% | -5.0% | +1.1% | +1.3% | -2.2% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.36 | $27.90 | -18.8% | -22.8% | -5.0% | +1.1% | +1.3% | -2.2% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.92 | $24.98 | +0.2% | +0.9% | +1.4% | -2.9% | -2.2% | +0.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.97 | $20.94 | -0.1% | -3.1% | -2.0% | -3.2% | +2.5% | +0.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.89 | $20.89 | +0.0% | +0.0% | +0.8% | -0.9% | +0.2% | -0.9% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.61 | $26.13 | -1.8% | -6.5% | +3.4% | +2.4% | -0.9% | -2.1% |
| Jan 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.27 | $26.19 | -0.3% | -2.3% | +0.3% | -2.2% | +0.9% | +5.2% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.03 | $27.74 | -1.0% | -3.1% | +2.5% | -2.4% | -6.9% | -0.6% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.43 | $32.38 | -0.2% | -2.4% | +0.3% | -5.1% | +0.1% | +0.5% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.45 | $34.78 | +4.0% | -3.0% | -2.4% | +0.3% | -5.1% | +0.1% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.65 | $28.99 | +1.2% | +1.6% | +1.3% | +0.0% | +2.4% | +5.7% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.85 | $29.68 | -0.6% | -5.6% | -3.9% | -0.6% | -3.0% | -2.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.16 | $26.50 | +1.3% | +6.3% | +1.1% | +4.5% | -2.4% | +1.0% |
| Jul 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.65 | $24.82 | +0.7% | -0.4% | +4.6% | +1.9% | +3.1% | -0.1% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.24 | $24.80 | -1.7% | +2.2% | -6.6% | +1.7% | -0.6% | -1.5% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.34 | $25.28 | -0.2% | +1.9% | -1.5% | -2.6% | +1.0% | -2.0% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.64 | $25.55 | -0.4% | -1.1% | +0.2% | +4.3% | -4.4% | +1.9% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.71 | $24.49 | -0.9% | +6.4% | -2.4% | -0.2% | +0.6% | +2.1% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.18 | $22.50 | +1.4% | +4.3% | -3.7% | +10.0% | -4.7% | -0.1% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.08 | $17.89 | -1.1% | +1.8% | +1.9% | -0.2% | +1.2% | -2.3% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.54 | $15.42 | -0.8% | +1.7% | +4.0% | +7.7% | -8.1% | -0.6% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.65 | $16.35 | +4.5% | +3.2% | +0.9% | +0.6% | -3.5% | -2.1% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.57 | $18.70 | +0.7% | +4.2% | -4.3% | -3.4% | +1.5% | +1.2% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.18 | $17.44 | +1.5% | -0.2% | -0.3% | +9.3% | -0.6% | +4.2% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.66 | $23.92 | +1.1% | +9.0% | +6.9% | -6.4% | -4.1% | +3.1% |
| Sep 9 | Aegis Capital | Maintains | Buy → Buy | — | $25.38 | $25.66 | +1.1% | +0.0% | +2.6% | -2.8% | -5.6% | +1.7% |
| Sep 7 | Wedbush | Downgrade | Outperform → Neutral | — | $28.88 | $27.00 | -6.5% | -12.5% | +0.5% | +0.0% | +2.6% | -2.8% |
| Sep 5 | Wedbush | Upgrade | Neutral → Outperform | — | $11.18 | $11.50 | +2.9% | +44.2% | -0.6% | +12.6% | +1.3% | -3.4% |
| Nov 14 | Wedbush | Downgrade | Outperform → Neutral | — | $6.58 | $6.70 | +1.8% | +2.6% | +8.6% | -1.2% | -3.7% | -4.6% |
| Jul 23 | Jefferies | Downgrade | Buy → Hold | — | $20.00 | $21.20 | +6.0% | +4.0% | -9.6% | -12.8% | +7.3% | -5.7% |
| Jun 29 | Susquehanna | Downgrade | Positive → Neutral | — | $78.40 | $77.00 | -1.8% | -6.6% | +6.0% | -3.4% | -0.5% | +3.5% |
| Mar 12 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $74.40 | $73.40 | -1.3% | +1.6% | -2.4% | +0.8% | +5.4% | +1.5% |
| Nov 10 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $76.20 | $75.60 | -0.8% | +2.4% | +3.6% | +1.0% | -2.7% | -1.3% |
| Apr 29 | McNicoll Lewis Vlak | Upgrade | Hold → Buy | — | $76.40 | $82.20 | +7.6% | +20.2% | -3.3% | -1.4% | -1.8% | +8.1% |
| Mar 11 | McNicoll Lewis Vlak | Downgrade | Buy → Hold | — | $128.60 | $122.00 | -5.1% | -8.7% | +3.2% | +1.5% | -2.1% | -1.2% |
| Mar 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $188.80 | $145.40 | -23.0% | -27.8% | -4.0% | -3.4% | +1.6% | -8.7% |
| Mar 4 | Credit Suisse | Downgrade | Outperform → Neutral | — | $178.20 | $182.20 | +2.2% | +5.9% | -27.8% | -4.0% | -3.4% | +1.6% |
| May 9 | Canaccord Genuity | Upgrade | Hold → Buy | — | $62.60 | $71.60 | +14.4% | +22.4% | +3.7% | +8.3% | -2.8% | +1.0% |
| Jan 7 | Wedbush | Maintains | Outperform → Outperform | — | $55.00 | $55.00 | +0.0% | +5.1% | +2.4% | +0.0% | -3.7% | -0.7% |
| May 9 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $62.00 | $61.20 | -1.3% | -11.9% | -9.5% | +6.1% | -1.1% | -2.7% |
| Mar 20 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $47.00 | $48.00 | +2.1% | -1.3% | +0.9% | -5.1% | -1.4% | +8.2% |
No insider trades available.
S-4
!!! Very High
XOMA Royalty Holdings Corp -- Merger Registration
XOMA Royalty Holdings will acquire XOMA Royalty through a merger, providing shareholders minimal cash consideration and potentially diluting existing equity holders.
May 26
8-K
XOMA Royalty Corp. -- 8-K Filing
May 22
8-K
Ligand Pharmaceuticals Incorporated -- 8-K Filing
May 18
8-K
XOMA Royalty Corp. -- 8-K Filing
May 18
8-K · 2.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 2.02: Earnings Results
Ligand Pharmaceuticals reported Q1 2026 financial results, providing investors updated performance metrics and operational insights for assessing the company's financial health and strategic progress.
May 7
8-K
XOMA ROYALTY CORP - XOMA 8 5/8 PERP -- 8-K Filing
Legendarily XOMA Royalty shareholders will receive cash and contingent value rights tied to RemainCo LLC interests in the merger, providing potential future payments beyond immediate consideration.
Apr 27
8-K
Unknown — 8-K Filing
XOMA's significant portfolio expansion of 22 assets and two platform technologies positions the royalty aggregator for diversified revenue streams and reduced single-asset dependency, making it attractive for investors seeking biotech exposure with lower development risk.
Mar 18
8-K · 7.01
! Medium
XOMA Royalty Corporation -- 8-K 7.01: Regulation FD Disclosure
XOMA Royalty Corporation disclosed information under Regulation FD, requiring simultaneous public disclosure to all investors to ensure fair access to material company information.
Mar 2
8-K
XOMA Royalty Corporation -- 8-K Filing
XOMA Royalty Corporation initiated a tender offer with an Offer to Purchase and Letter of Transmittal filed on Schedule TO, allowing shareholders to tender shares under specified terms.
Feb 9
8-K
XOMA Royalty Corporation -- 8-K Filing
XOMA Royalty Corporation completed its post-offer reorganization with LAVA on November 20, 2025, concluding the subsequent offering period and effectuating the planned corporate restructuring.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 3,429,336 | $91M | Added | Dec 2025 |
| 2 | Fmr Llc | 1,302,974 | $41M | Added | Mar 2026 |
| 3 | Woodline Partners Lp | 640,001 | $20M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 549,796 | $17M | New | Mar 2026 |
| 5 | Opaleye Management Inc. | 292,590 | $8M | Added | Dec 2025 |
| 6 | Millennium Management | 204,920 | $6M | New | Mar 2026 |
| 7 | Tls Advisors Llc | 114,867 | $4M | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 98,638 | $3M | New | Mar 2026 |
| 9 | Northern Trust Corp | 93,490 | $3M | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 85,797 | $3M | New | Mar 2026 |
| 11 | Bank Of New York Mellon Corp | 74,984 | $2M | Added | Mar 2026 |
| 12 | Ubs Group Ag | 72,533 | $2M | Added | Mar 2026 |
| 13 | Stonepine Capital Management, Llc | 69,500 | $2M | Reduced | Mar 2026 |
| 14 | Simcoe Capital Llc | 68,053 | $2M | New | Mar 2026 |
| 15 | Rbf Capital, Llc | 60,000 | $2M | — | Mar 2026 |
| 16 | Panagora Asset Management Inc | 58,662 | $2M | Added | Mar 2026 |
| 17 | Cm Management, Llc | 40,000 | $1M | Reduced | Dec 2025 |
| 18 | Quadrature Capital Ltd | 28,495 | $894K | New | Mar 2026 |
| 19 | Two Sigma Investments, Lp | 26,075 | $818K | Added | Mar 2026 |
| 20 | Susquehanna International Group, Llp | 17,390 | $546K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$526.9M
Enterprise Value
$786.9M
P/E (TTM)
23.91x
Forward P/E
37.38x
PEG Ratio
-0.08x
P/B
7.27x
P/S
20.85x
P/FCF
263.15x
EV/EBITDA
15.69x
Shares Out
18.0M
Financials (TTM)
Revenue
$36.2M
Net Income
$31.5M
EBITDA
$50.2M
Free Cash Flow
$2.9M
Op Cash Flow
$2.9M
EPS Basic
$1.53
EPS Diluted
$1.57
EPS Forward
$1.12
Gross Margin
93.3%
Op Margin
13.7%
Net Margin
87.0%
Balance Sheet
Total Assets
$272.7M
Total Liab.
$168.7M
Total Equity
$104.0M
Cash
$82.9M
LT Debt
$116.6M
Book Value/Sh
$5.78
Debt/Equity
1.27x
Current Ratio
3.37
Quick Ratio
3.37
Returns & Growth
ROE
37.8%
ROA
11.6%
ROIC
4.5%
Rev Growth YoY
+83.1%
EPS Growth YoY
+192.7%
Price Returns
2W
-0.7%
1M
+1.9%
3M
+63.4%
6M
+29.8%
12M
+68.5%
Technicals
52W High
$42.81
52W Low
$22.29
50d MA
$41.00
200d MA
$33.24
RSI (14)
54.40
ATR (14)
$0.36
Beta
0.68
Avg Volume
108K
Dividends
Div Rate
$0.30
Div Yield
0.7%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$53.75
High
$76.00
Low
$39.00
Median
$50.00
Data updated apr 27, 2026 10:41am
· Source: financialmodelingprep.com